Protein Engineering in Structure-Function Studies of Viper's Venom Secreted Phospholipases A₂

Toni Petan¹, Petra Prijatelj Žnidaršič² and Jože Pungerčar¹

¹*Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana,*

²*Department of Chemistry and Biochemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia*

1. Introduction

Secreted phospholipases A₂ (sPLA₂s) constitute a large family of interfacial enzymes that hydrolyze the *sn*-2 ester bond of membrane glycerophospholipids, releasing free fatty acids and lysophospholipids (Murakami et al., 2011). They are abundant in snake venoms, frequently being their major toxic components, and display a variety of pharmacological effects, such as neurotoxicity, myotoxicity, anticoagulant activity, cardiotoxicity and haemolytic activity. The molecular mechanisms underlying these effects are still poorly understood; but they are most probably based on the existence of specific, high-affinity binding sites for toxic sPLA₂s on the surface of target cells in specific target tissues (Kini, 2003). Snakes have developed, through evolution, an arsenal of structurally similar molecules that target a specific tissue or function, in order to capture and digest their prey. Interestingly, very often a particular sPLA₂ molecule may display, despite its simple, globular and compact structure, several different toxic activities. Thus, it significantly expands the possible prey-damaging mechanisms of the venom, which also depend on the type of prey, site of injection of the toxin and the tissue involved. The remarkable variety of pharmacological effects exerted by sPLA₂ toxins is a consequence of several factors that have intrigued scientists working in the field, but have also greatly complicated the study of their actions. The complications include (1) the apparently indiscriminate enzymatic activities of sPLA₂ toxins on different cellular and non-cellular phospholipid membranes and aggregates; (2) the diverse effects of the products of the hydrolysis of sPLA₂ toxins, especially on membrane structural integrity and dynamics, thus affecting the major structural and functional features of the cell; and (3) the ever increasing diversity of sPLA₂ intra- and extracellular binding proteins discovered in mammalian tissues, which are involved in very different biological processes. Additionally, many of the actions of sPLA₂ toxins involve complex, multi-step molecular mechanisms, in which a specific combination of enzymatic activity and/or protein binding is probably essential for a particular step. Although sPLA₂s are structurally highly conserved proteins, it is clear that subtle evolutionary changes of residues on the surface of the molecule have empowered these enzymes with this wide range of toxic activities. Their ability to recognize specific molecular

targets has been gradually optimized and thus interferes with a range of physiological processes (Kini & Chan, 1999). Snakes have even developed, through their evolution, catalytically inactive sPLA₂-homologues specialized in membrane damage that occurs independently of enzymatic activity (Lomonte et al., 2009). Interestingly, a range of structurally very similar sPLA₂ enzymes, as well as an enzymatically inactive sPLA₂ homologue, are also present in mammals. The mammalian sPLA₂ family consists of 10 or 11 enzymes (Lambeau & Gelb, 2008) that display different cell- and tissue-specific expression patterns. The proteins act with a broad range of enzymatic activities on a variety of cellular and non-cellular phospholipid membranes (Murakami et al., 2011). They bind with high affinity to various soluble and membrane protein targets, many of which were discovered using toxic sPLA₂s (Pungerčar & Križaj, 2007; Valentin & Lambeau, 2000). Furthermore, apart from their direct effects on membrane structure and function, the products of their catalysis are precursors of hundreds of bioactive lipid signalling molecules, such as the eicosanoids. The mammalian sPLA₂ enzymes display a similarly broad range of roles, mostly incompletely understood and often contradictory, in various physiological and pathophysiological processes, such as lipid digestion and homeostasis, innate immunity, inflammation, fertility, blood coagulation, asthma, atherosclerosis, autoimmune diseases and cancer (Lambeau & Gelb, 2008; Murakami et al., 2011). In this they are analogous to their venom counterparts, owing their functions to a combination of enzymatic activity, direct and indirect effects of the products of their hydrolysis, and specific interactions with molecular partners inside or outside the cell. The research on the action of exogenous snake venom sPLA₂ enzymes, which target particular physiological processes in their mammalian prey, has been providing important clues for deciphering the biological roles of the mammalian endogenous sPLA₂ enzymes as well (Rouault et al., 2006; Valentin & Lambeau, 2000).

The most potent sPLA₂ toxins display presynaptic (β -)neurotoxicity by attacking the presynaptic site of neuromuscular junctions. The venom of the nose-horned viper, *Vipera ammodytes ammodytes*, contains three presynaptically neurotoxic sPLA₂s, ammodytoxins (Atxs) A, B and C, two non-toxic ammodytins (Atns), AtnI₁ and AtnI₂, and a myotoxic and catalytically inactive Ser49 sPLA₂ homologue, ammodytin L (AtnL). They are all group IIA sPLA₂s. The presynaptically acting (β -neurotoxic) Atxs interfere specifically with the release of acetylcholine from motoneurons and cause irreversible blockade of neuromuscular transmission. The exact mechanism of their action is not yet fully understood, but it must include specific binding to receptor(s) on the presynaptic membrane and enzymatic activity (Montecucco et al., 2008; Pungerčar & Križaj, 2007). The binding to highly specific, and yet unknown, primary molecular targets of β -neurotoxins (β -ntxs) on the presynaptic membrane is most probably followed by entry of the toxin into the nerve cell (Logonder et al., 2009; Pražnikar et al., 2008; Rigoni et al., 2008). It has been proposed that different sPLA₂-toxins exploit different internalization routes (Pungerčar & Križaj, 2007). In the motoneuron, they may impair the cycling of synaptic vesicles by phospholipid hydrolysis and by binding to specific intracellular protein targets, like calmodulin (Kovačič et al., 2009, 2010; Šribar et al., 2001) and 14-3-3 proteins (Šribar et al., 2003b) in the cytosol, and R25 (Šribar et al., 2003a) in mitochondria. Although the role of enzymatic activity in β -neurotoxicity of sPLA₂s is still somewhat controversial, accumulated results speak largely in favour of its being indispensable for full expression of the β -neurotoxic effect (Montecucco et al., 2008; Pungerčar & Križaj, 2007; Rouault et al., 2006).

In spite of numerous attempts to identify the surface residues of sPLA₂s crucial for a particular pharmacological effect (i.e., the “ β -neurotoxic site” or the “anticoagulant site”) – based initially on structural analysis, chemical modification and, later on, site-directed mutagenesis, the molecular basis of their toxicity has yet to be resolved (Kini, 2003; Križaj, 2011; Pungertar & Križaj, 2007; Rouault et al., 2006). We have addressed this issue in studies based on protein engineering of the nosed-horned viper sPLA₂s. These have resulted in more than fifty mutants and chimeric sPLA₂ proteins that have been produced and characterized in terms of their biochemical and biological activities (most of them are shown in Table 1). The site-directed mutagenesis studies have provided answers to, or at least significantly improved, our knowledge concerning many important questions regarding the toxic and enzymatic activities of Atxs and other sPLA₂s, such as:

- Which regions of the molecule are important for the β -neurotoxicity of Atxs and homologous toxic sPLA₂s?
- Which surface residues of Atxs are crucial for interaction with their high-affinity binding proteins? Is there a correlation between the affinity for binding to a particular protein target and the neurotoxic potency of Atxs, suggesting a role for the receptor protein in the process?
- Which residues are responsible for interfacial membrane binding of Atxs? How do the interfacial membrane and kinetic properties of Atxs influence their toxic action? How do the enzymatic properties of Atxs compare with those of the best-studied mammalian sPLA₂s?
- What is the importance of the loss in evolution of enzymatic activity in the case of the AtnL and other myotoxic sPLA₂-homologues?

The results obtained have contributed significantly to a better understanding of the molecular mechanisms of action of snake venom sPLA₂s and provided clues to the action of the homologous groups of mammalian sPLA₂s.

2. Search for the “neurotoxic site” and the role of enzymatic activity

The significant structural similarities of toxic and non-toxic sPLA₂s, which differ in their pharmacological actions, have enticed a large number of researchers hoping to find the “holy grail” of sPLA₂-toxin research – the toxic site. The site is presumed to comprise only a small number of crucial amino acid residues (Kini, 2003). To explain the wide range of pharmacological effects induced by snake venom sPLA₂s, Kini & Evans (1989) proposed a model comprising specific “target sites” present on the surface of particular cell types. The target sites are proposed to be recognized by complementary “pharmacological sites” on the toxin molecule, these being structurally distinct from, and independent of, the “catalytic site.” Thus, high-affinity binding (at least in the nM range) of the toxin to specific target sites ensures that, upon entering the circulation, each toxin binds primarily to its proper target tissue. It is highly likely that the primary target, or acceptor, sites are proteins. This is because of the much lower affinity (mM– μ M range) of sPLA₂s for binding to the abundant zwitterionic phospholipid surfaces (i.e., cell membranes) (Bezzine et al., 2002; Petan et al., 2005; Singer et al., 2002) and, following enzyme adsorption to the membrane surface, indiscriminate binding to and hydrolysis of phospholipid molecules at the catalytic site. Therefore, separate pharmacological sites on an sPLA₂ molecule recognizing different target binding sites should be the main structural determinants that differentiate their respective

pharmacological actions, such as presynaptic or central neurotoxicity. However, according to the results of our mutagenesis structure-function studies of Atxs reviewed below, it is unlikely that there is a structurally distinct, single “presynaptic neurotoxic site” located in a specific part of the molecule, in contrast to the strict physical localization of the enzyme active site. Rather, different parts of the toxin molecule are likely to be involved in different stages of the complex multi-step process of neurotoxicity, all contributing to the final outcome. In this view, structurally different β -ntxs may have different surface regions that bind to different (extra- and intracellular) targets, which are nevertheless involved in the same process, most probably the recycling of synaptic vesicles. However, they all share the nonspecific sPLA₂ activity, i.e., the ability to bind and hydrolyze different phospholipid molecules embedded in membranes of various compositions – an essential step in the complete, irreversible blockade of neuromuscular transmission. Therefore, at least in the case of β -neurotoxic sPLA₂s, the use of the term “presynaptic neurotoxic site” appears unsuitable for describing the multiple regions distributed on the surface of the sPLA₂ molecule (Prijatelj et al., 2008).

Given the multi-step, and as yet incompletely known, molecular events leading to presynaptic neurotoxicity of sPLA₂s, a simple correlation between their *in vitro* enzymatic activity and their lethal potency would not be expected (Rosenberg, 1997). Indeed, there are numerous examples of sPLA₂ β -ntxs with significantly different enzymatic properties, which are, however, not reflected in differences in toxicity; in fact even the most potent sPLA₂ β -ntxs are weak enzymes (Petan et al., 2005; Pražnikar et al., 2008; Prijatelj et al., 2006b, 2008; Rosenberg, 1997). Nevertheless, sPLA₂ enzymatic activity is necessary for full expression of the β -neurotoxic effect (Montecucco et al., 2008; Pungerčar & Križaj, 2007). Its role in the process is most probably obscured by the numerous factors affecting both sPLA₂ activity and neurotoxicity, especially the, as yet unknown, (sub)cellular location, accessibility, composition and physical properties of the target membrane. The enzymatic action of sPLA₂s could lead to structural and functional destruction of cell membranes and organelles, like mitochondria or synaptic vesicles (Pražnikar et al., 2008, 2009; Pungerčar & Križaj, 2007; Rigoni et al., 2008), since the products of phospholipid hydrolysis are disruptive to many physiological processes by impairing the function of peripheral and integral membrane proteins and promoting membrane dysfunction by altering membrane asymmetry, curvature and fusogenicity (Montecucco et al., 2008; Paoli et al., 2009; Rigoni et al., 2005). The apparent lack of correlation between *in vitro* enzymatic activity and lethal potency of Atxs or other neurotoxic sPLA₂s (Montecucco et al., 2008; Petan et al., 2005; Pungerčar & Križaj, 2007) can be explained by the strict localization of the sPLA₂ activity to particular target membrane(s) due to binding to highly specific extra- and intracellular protein acceptors (Paoli et al., 2009; Petan et al., 2005; Pungerčar & Križaj, 2007). Our studies investigating the interfacial binding and kinetic properties of toxic sPLA₂s and their mutants have provided important clues to understanding the role of enzymatic activity in the process of presynaptic neurotoxicity of sPLA₂s. As described in detail below, despite their potent neurotoxic activity, Atxs are quite effective in hydrolysing pure phosphatidylcholine (PC) vesicles as well as PC-rich plasma membranes of mammalian cells, similarly to the most active mammalian group V and X sPLA₂ enzymes (Petan et al., 2005, 2007; Pražnikar et al., 2008). We have also shown that, when tightly bound to the membrane surface, the Ca²⁺ requirements of Atxs are in the micromolar range (Petan et al., 2005), opening up the possibility that such neurotoxins are also catalytically active in the subcellular

compartments where Ca^{2+} concentrations are low (Kovačič et al., 2009; Petan et al., 2005). Moreover, Atxs are rapidly internalized in motoneuronal cells and are, surprisingly, translocated to the cytosol, where they specifically bind calmodulin (CaM) and 14-3-3 proteins, strongly opposing the dogma of the exclusively extracellular action of not only sPLA₂-neurotoxins, but also of sPLA₂s in general (Pražnikar et al., 2008). In agreement with these findings, we have recently shown that high-affinity binding to the cytosolic Ca^{2+} -sensor molecule CaM leads to structural stabilization (increased resistance to the reducing environment of the cytosol) and a significant augmentation of the enzymatic activity of Atxs and, intriguingly, also of the mammalian group V and X sPLA₂s (Kovačič et al., 2009, 2010). These findings strongly support the possibility of augmentation of Atx enzymatic activity by CaM in the cytosol during the process of β -neurotoxicity. They also point to a new mechanism of modulating the enzymatic activity of mammalian group V and X sPLA₂s or some other non-toxic endogenous sPLA₂ (Kovačič et al., 2010).

3. Structural determinants of presynaptic neurotoxicity of sPLA₂s

The subtlety of the structure-function relationship of sPLA₂ neurotoxins is obvious on examination of the primary structures and toxicities of Atxs. The three sPLA₂ toxins each consist of 122 amino acid residues and differ at only five positions (Križaj, 2011). AtxC may be considered as a natural double mutant (F124I/K128E) and AtxB as a triple mutant (Y115H/R118M/N119Y) of AtxA. Nevertheless, their lethal potencies in mice differ considerably. AtxA is the most lethal; and its protein isoforms, AtxC and AtxB, are 17- and 28-fold less potent, respectively (Thouin et al., 1982). The crystal structures of recombinant AtxA (PDB code 3G8G) and natural AtxC (PDB code 3G8H) demonstrate the absence of significant structural differences between the two toxins (Saul et al., 2010). There is only a minor conformational difference at positions 127 and 128 in the C-terminal region, caused by the charge-reversal substitution of Lys128 for Glu, which does not significantly influence the toxicity (Saul et al., 2010). An illustrative example of the subtle structure-function relationships of sPLA₂s is the conversion, by a single mutation (F22Y), of the gene for bovine pancreatic group IB sPLA₂ to a gene encoding a molecule able to compete with crotoxin, a β -neurotoxic sPLA₂ from the South American rattlesnake, *Crotalus durissus terrificus*, for binding to its 45-kDa neuronal-binding protein. This led the authors to suggest the conversion of the non-toxic pancreatic sPLA₂ to a neurotoxic molecule (Tzeng et al., 1995).

By substituting several basic residues in the C-terminal region (AtxA^{NNTE} mutant: AtxA-K108N/K111N/K127T/K128E/E129T/K132E) and in the β -structure region (AtxA^{SSL} mutant: AtxA-K74S/H76S/R77L) with acidic and non-ionic residues, we have shown, contrary to previous beliefs, that the basic character of Atxs, and probably of other β -neurotoxic sPLA₂s, is not obligatory for presynaptic toxicity (Ivanovski et al., 2004; Prijatelj et al., 2000; Table 1). According to our earlier structure-function analyses, the more than one order of magnitude lower toxicity of AtxC than that of AtxA is a consequence of the substitution of the aromatic Phe124 by Ile (Pungerčar et al., 1999). Furthermore, in accordance with the three substitutions responsible for the difference in toxicities of AtxA and AtxB, several other C-terminal residues of AtxA, namely the Tyr115/Ile116/Arg118/Asn119 (YIRN) cluster, were shown to be important for the neurotoxicity of Atxs (Ivanovski et al., 2000). Thus, the lethal potency of the AtxA-Y115K/I116K/R118M/N119L (AtxA^{KKML}) mutant was 290-fold lower than that of AtxA (Ivanovski et al., 2000 and Table 1).

sPLA ₂	LD ₅₀ (μg/kg)	IC ₅₀ (nM)			References
		CaM	R25	R180	
AtxA	21	6 ± 2	10 ± 3	16 ± 3	<i>a, b</i>
AtxB	580	23 ± 4	n. d.	n. d.	<i>a, c</i>
AtxC	360	21 ± 3	50	155	<i>a, c, d, e</i>
12-AtxA	280	72 ± 15	5 ± 2	> 10 ⁴	<i>f</i>
I-AtxA	500	250 ± 60	3.4 ± 0.3	> 10 ⁴	<i>f</i>
P-AtxA	420	380 ± 85	3.5 ± 0.5	> 10 ⁴	<i>f</i>
AtnI ₂ /AtxA ^{K108N}	> 10 ⁴	1300 ± 200	20 ± 6	490 ± 100	<i>g</i>
AtnI ₂ ^{N24F} /AtxA ^{K108N}	> 5000	1700 ± 300	24 ± 6	850 ± 200	<i>g</i>
AtnI ₂	> 10 ⁴	> 10 ⁴	> 10 ⁴	610 ± 100	<i>g</i>
AtxA ^{NNTTETE}	660	27 ± 5	16	100	<i>c, d</i>
AtxA ^{K108N/K111N}	67	17 ± 4	38	68	<i>c, d, h</i>
AtxA ^{K127T}	35	20 ± 3	22	300	<i>c, d</i>
AtxA ^{K128E}	45	14 ± 3	n. d.	n. d.	<i>c, h</i>
AtxA ^{F24A}	90	7.0 ± 0.9	15 ± 1	17 ± 2	<i>b</i>
AtxA ^{F24N}	2800	5.6 ± 0.7	14 ± 2	26 ± 1	<i>b</i>
AtxA ^{F24S}	380	7.4 ± 0.2	14 ± 1	16 ± 2	<i>b</i>
AtxA ^{F24W}	175	13.6 ± 0.3	37 ± 5	26 ± 3	<i>b</i>
AtxA ^{F24Y}	330	9.2 ± 0.9	14 ± 3	19 ± 4	<i>b</i>
AtxA ^{V31W}	135	n. d.	n. d.	n. d.	<i>i</i>
AtxA ^{R72E}	84	71 ± 3	14 ± 1	78 ± 7	<i>j</i>
AtxA ^{R72I}	32	17 ± 2	18.0 ± 0.4	28 ± 3	<i>j</i>
AtxA ^{R72K}	50	46 ± 2	11.7 ± 0.4	83 ± 9	<i>j</i>
AtxA ^{R72S}	55	24 ± 2	16 ± 1	35 ± 1	<i>j</i>
AtxA ^{SSL}	276	18 ± 1	18 ± 1	107 ± 8	<i>j</i>
AtxA ^{K86A}	24	8.1 ± 0.3	15 ± 1	20 ± 3	<i>j</i>
AtxA ^{K86E}	32	7 ± 1	18 ± 1	42 ± 4	<i>j</i>
AtxA ^{K86G}	34	7.5 ± 0.2	12.1 ± 0.1	65 ± 4	<i>j</i>
AtxA ^{K86R}	31	8.8 ± 0.5	16.3 ± 0.5	36 ± 1	<i>j</i>
AtxA ^{KKML}	~ 6000	50 ± 9	86	257	<i>c, k</i>
AtxA ^{KK}	~ 5000	21 ± 3	380	118	<i>c, k</i>
AtxA/DPLA ₂ ^{YIRN}	45	27 ± 5	180 ± 25	100 ± 16	<i>l</i>
AtxA ^{KEW} /DPLA ₂ ^{YIRN}	910	43 ± 12	110 ± 15	22 ± 4	<i>l</i>
AtxA ^{KE} /DPLA ₂ ^{YIRN}	790	14 ± 4	87 ± 9	24 ± 4	<i>l</i>
AtxA ^W /DPLA ₂ ^{YIRN}	107	28 ± 7	78 ± 12	19 ± 5	<i>l</i>
AtxA/DPLA ₂	2600	110 ± 10	45% [#]	280 ± 19	<i>l</i>
DPLA ₂ ^{YIRN}	~ 17000	43 ± 14	200 ± 30	120 ± 21	<i>c, l</i>
DPLA ₂	3100	300 ± 36	75% [#]	300 ± 45	<i>c, l</i>
AtnL	> 10000	n. d.	n. d.	n. d.	<i>m</i>
AtnL ^{YVGD}	> 7000	n. d.	n. d.	n. d.	<i>m</i>
AtnL ^{YWGD}	2200	n. d.	n. d.	n. d.	<i>m</i>

Table 1. Lethal potency and protein-binding affinity of Atxs, Atns, DPLA₂ and their mutants. IC₅₀ values (the concentration of competitor sPLA₂ required to reduce the binding of 10 nM ¹²⁵I-AtxC by 50%) were determined from competition binding experiments for binding to calmodulin (CaM), the mitochondrial receptor R25 and the neuronal M-type sPLA₂ receptor, R180. [#]The recombinant toxin did not completely inhibit the binding of ¹²⁵I-AtxC. ^aThouin et al., 1982; ^bPetan et al., 2002; ^cPrijatelj et al., 2003; ^dPrijatelj et al., 2000; ^eČopić et al., 1999; ^fPrijatelj et al., 2006b; ^gPrijatelj et al., 2002; ^hPungerčar et al., 1999; ⁱPetan et al., 2005; ^jIvanovski et al., 2004; ^kIvanovski et al., 2000; ^lPrijatelj et al., 2008; ^mPetan et al., 2007.

The KKML cluster is present in the weakly neurotoxic DPLA₂ from the venom of Russell's viper, *Daboia (Vipera) russelii russelii*, which shares a high level of amino acid identity (82%) with AtxA. However, the latter is almost 150-fold more toxic in mice (Priatelj et al., 2003). To our great surprise, the introduction of the YIRN cluster into DPLA₂ did not increase its toxicity; on the contrary, the DPLA₂^{YIRN} mutant was more than five times less toxic than DPLA₂ (Priatelj et al., 2003). Additionally, our study on the importance of the N-terminal residue Phe24, in which it was replaced by other aromatic (tyr or trp), polar uncharged (ser or asn) or hydrophobic (ala) residues, suggested that Phe24 is also involved in the neurotoxicity of Atxs, apparently at a stage not involving enzymatic activity or interactions with the high-affinity binding proteins R25, R180 and CaM (Petan et al., 2002). The aromatic Phe24 was chosen for this study on the basis of several interesting characteristics. It is located in a region immediately preceding the Ca²⁺-binding loop, but it is spatially close to the important Phe124. It is important for membrane binding as part of the interfacial binding surface (IBS, see below) of the enzyme, and it is replaced by ser in the weakly neurotoxic DPLA₂. These facts prompted us to propose that a particular combination of both C-terminal and N-terminal residues must be involved in β -neurotoxicity. In order to identify the N-terminal residues that supplement the role of the YIRN cluster in the high neurotoxic potency of AtxA, we selectively mutated some of the remaining residues that differentiate DPLA₂ from AtxA. First, we introduced the N-terminal half of AtxA into DPLA₂ by preparing the chimeric AtxA/DPLA₂ protein. Its lethal potency was relatively low, in the range of those of DPLA₂ and the AtxA^{KKML} mutant (Table 1 and Ivanovski et al., 2000), confirming that it is primarily the presence of the KKML cluster in the C-terminus of the chimera that has a strong negative influence on toxicity. Secondly, by substituting the KKML cluster in DPLA₂ with the YIRN cluster of AtxA, we produced a chimeric mutant (AtxA/DPLA₂^{YIRN}) that is 58-fold higher in lethal potency than is AtxA/DPLA₂, reaching a level of toxicity similar to that of the highly neurotoxic AtxA. Thus, only in combination with the N-terminal part of AtxA is the presence of the YIRN cluster sufficient for the high neurotoxic potency of AtxA and AtxA/DPLA₂^{YIRN}. This allowed us to exclude the importance of the additional eleven C-terminal residues present in AtxA and absent in DPLA₂ – Thr70, His76, Glu78, Gly85, Arg100, Asn114, Ser130, Glu131 – and was in accordance with the findings of our early mutagenesis study on the three C-terminal lysines at positions 108, 111 and 128 (Pungerčar et al., 1999) (Figure 1). These results clearly confirmed our hypothesis that a particular combination of C-terminal residues, especially those in the region 115-119, i.e., the YIRN cluster, and certain N-terminal residues are necessary for the potent β -neurotoxicity of Atxs.

Our next objective was to determine the contribution to the high neurotoxic potency of AtxA of the remaining nine N-terminal residues that differentiate it from DPLA₂ (Met7, Gly11, Asn17, Pro18, Leu19, Thr20, Phe24, Val31 and Ser67). As described above, the importance of the aromatic Phe24 had already been established (Petan et al., 2002). In order to assess the importance of the remaining N-terminal residues, we first substituted Met7, Gly11 and Val31 in the highly toxic chimera AtxA/DPLA₂^{YIRN} by the corresponding residues present in DPLA₂ – lys, glu and trp, respectively. The mutant protein AtxA^{KEW}/DPLA₂^{YIRN} displayed a 20-fold lower lethal potency than the AtxA/DPLA₂^{YIRN} chimera, suggesting involvement of the group of residues at positions 7, 11 and 31 in AtxA neurotoxicity. The lethality of the partial mutants, AtxA^{KE}/DPLA₂^{YIRN} and AtxA^W/DPLA₂^{YIRN} (Table 1), revealed that the contribution of the pair of residues in the N-terminal helix, Met7 and Gly11, to the

	1	10	20	30	40	50	60
AtxA	S	LLEFGMMILG-	ETGKNPLT	SYSF ^y	YGCYCGVGGKGT	PKDATDRCCFVHDCCYGNLP--D-C-----S	
AtxB	.	-				--.-.-----.	
AtxC	.	-				--.-.-----.	
AtxA ^{KKML}	.	-				--.-.-----.	
AtxA/DPLA ₂ ^{YIRN}	.	-				--.-.-----.	
AtxA ^{KEW} /DPLA ₂ ^{YIRN}	.	K...E-		.W.....		--.-.-----.	
AtxA/DPLA ₂	.	-				--.-.-----.	
DPLA ₂ ^{YIRN}	.	K...E-...LAIP..S.....W.....				--.-.-----N	
DPLA ₂	.	K...E-...LAIP..S.....W.....				--.-.-----N	
AtnL	.	VI...K..QE-.D.....H..LN.K.....S...AK.S--.-.-----.					
AtnL ^{YVGD}	.	VI...K..QE-.D.....V...K.....AK.S--.-.-----.					
AtnL ^{YWGD}	.	VI...K..QE-.D.....W...K.....AK.S--.-.-----.					
AtnI ₂	N.YQ..N..FK-M.K.SA.L...N.....W...K.Q.....RVN--G------D						
hGIIA	N.VN.HR..KL-T...EAAL..G...H...R.S.....VT...KR.EKRG------G						
hGV	G...DLKS..EK-V...A..N.G...W..R...G.W.WA..H...R.EEKG------N						
hGX	GI...LAGTVGC-V-.PRTPIA.MK...F..L..H.Q.R..I.W..HG.....TRAEEAG------.						
	70	80	90	100	110	120	130
AtxA	P	KTDR	RYKYHRENGAIVCGK-GTSCENRICECDRAAAICFRKNLKTYNYIYRNYPD-F	LCKK	ESEKC		
AtxB	.	-			H..MY..-.-.-----.		
AtxC	.	-			-I..E.....		
AtxA ^{KKML}	.	-		KK.ML..-.-.-----.			
AtxA/DPLA ₂ ^{YIRN}	.	S.....K.V.....E-.....K.....Q.N.S.....-...G-L..					
AtxA ^{KEW} /DPLA ₂ ^{YIRN}	.	S.....K.V.....E-.....K.....Q.N.S.....-...G-L..					
AtxA/DPLA ₂	.	S.....K.V.....E-.....K.....Q.N.SKK.ML..-...G-L..					
DPLA ₂ ^{YIRN}	.	S.....K.V.....E-.....K.....Q.N.S.....-...G-L..					
DPLA ₂	.	S.....K.V.....E-.....K.....Q.N.SKK.ML..-...G-L..					
AtnL	..N..E.....S-S.P.KKQ.....E.....KK.KV.LR-K..GV...						
AtnL ^{YVGD}	..N..E.....S-S.P.KKQ.....E.....KK.KV.LR-K..GV...						
AtnL ^{YWGD}	..N..E.....S-S.P.KKQ.....E.....KK.KV.LR-K..GV...						
AtnI ₂	..LSI.S.SF...D...G-DDP.LRAV...V...GE..N.DKK.K...S-SH.TET-Q.						
hGIIA	T.FLS..FSNSGSR.T.A.-QD..RSQL...K...T..AR.KT...KK.QY.SN-KH.RGSTPR.						
hGV	IR.QS...RFAW.VVT.EP-.PF.HVNLA...KLVS.LKR..RS..PQ.QYF.N-I..S						
hGX	...E..SWOCV.OSVL..PAENK.OELL.K.OEI.N.LAOT--E..LK.LF..O-...EPD.P..						

Fig. 1. Amino acid alignment of snake venom group IIA sPLA₂s, including the sPLA₂-homologue ammodytin L (AtnL), some of their mutants and the human group IIA, V and X sPLA₂s. The residues comprising the putative IBS of Atxs are presented in bold type, while those most important for the neurotoxicity of ammodytins (Atxs) are underlined. The weakly neurotoxic sPLA₂ from Russell's viper, *Daboia r. russelii*, DPLA₂, differs from AtxA in only 22 residues (82% identity). AtnL, the enzymatically inactive but myotoxic Ser49

structural homologue of Atxs, displays 74% amino acid identity with AtxA. The neutral ammodytin I₂ (AtnI₂) is a non-toxic homologue of Atxs from the same venom with 58% amino acid identity with AtxA. Atxs also display a relatively high degree of identity (48%) with the human groups IIA (hGIIA), V (hGV) sPLA₂s, and X (hGX) sPLA₂ (41%). The common sPLA₂ numbering of residues was used (Renetseder et al., 1985). Gaps, represented by dashes, were used to align the homologous sPLA₂s according to conserved residues. Identical amino acid residues are shown by dots. Amino acid single-letter symbols are shown in Table 1 in the chapter by Figurski et al.

neurotoxic potency of AtxA is substantially higher than that of Val31 – in accordance with the negligible effect of the V31W mutation on the lethality of AtxA, despite its outstanding effect on enzymatic activity (Petan et al., 2005). Interestingly, the bulky Trp at position 31 of the AtxA^{V31W} and AtxA^W/DPLA₂^{YIRN} mutants had no significant impact on neurotoxicity, despite being spatially very close to Phe24 and also to the YIRN cluster. The collective contribution of the N-terminal residues Met7, Gly11 and Phe24 to the neurotoxicity of AtxA is very significant and similar to that of the YIRN cluster in the C-terminus. For example, the substitution of Phe24 with ser in AtxA caused an approximately 19-fold decrease in neurotoxicity (Petan et al., 2002), which is similar to the reduction seen after adding the N-terminal region of AtxA^{KEW}, in which the residues Met7, Gly11 and Val31 were substituted with lys, glu and trp, respectively, to DPLA₂^{YIRN}, resulting in the AtxA^{KEW}/DPLA₂^{YIRN} chimeric mutant. Therefore, it is highly likely that the remaining N-terminal residues differentiating AtxA and DPLA₂, i.e., the Asn17/Pro18/Leu19/Thr20 cluster and Ser67, are not greatly involved in neurotoxicity.

Our structure-function studies of β -neurotoxic sPLA₂s (Ivanovski et al., 2000, 2004; Petan et al., 2002, 2005; Prijatelj et al., 2000, 2002, 2003, 2006b, 2008; Pungerčar et al., 1999) clearly show that different parts of the toxin molecule have separate roles in the distinct steps of the complex mechanism of presynaptic neurotoxicity (Pungerčar & Križaj, 2007). Most significantly, by selectively mutating parts of the DPLA₂ molecule, we were able to map the residues that separate the weakly β -neurotoxic sPLA₂ from the 150-fold more potent AtxA (Prijatelj et al., 2008). In summary, the most important structural features responsible for the high neurotoxic potency of Atxs (Figure 2, A) are: the “upper” part of the molecule concentrated around the C-terminal region 115-119 (the YIRN cluster) and including the spatially close aromatic Phe124 and Phe24, and the N-terminal helix region with the Met7/Gly11 pair in the “lower right” part of the molecule.

4. Enzymatic activity of Atxs: factors influencing interfacial binding and hydrolysis of phospholipid membranes

Secreted PLA₂s are prototypical interfacial enzymes (Berg et al., 2001). In order to gain access to their phospholipid substrate, sPLA₂s first have to bind at the lipid/water membrane interface by their interfacial binding surface (IBS), a group of residues located on a relatively flat exposed region surrounding the entrance to the active site pocket (Lin et al., 1998; Ramirez & Jain, 1991). Only then, after the enzyme is bound to the surface, can binding of a single phospholipid molecule and its hydrolysis occur in the active site. The catalytic turnover cycle of sPLA₂s includes a highly conserved His48–Asp99 dyad and an activated water molecule that acts as a nucleophile during hydrolysis of the *sn*-2 ester bond of the phospholipid (Scott et al., 1990). The resulting tetrahedral intermediate is stabilized by the

Fig. 2. Surface residues of ammodytotoxin A (AtxA) responsible for A) presynaptic neurotoxicity, B) interfacial membrane binding, C) binding to calmodulin and D) binding to factor Xa. The molecule is oriented with the interfacial binding surface (IBS) and the N-terminal residues facing the viewer, while the C-terminal region is located in the upper-left corner of the molecule; and the β -structure, in the lower-right corner. A) The conserved sPLA₂ helical structures are labelled with alphabet letters (red) (see section 4.1 for details; Saul et al., 2010). Residues important for neurotoxicity are presented in orange mesh surface and extend from the C-terminal region 115–119 (the YIRN cluster), including the spatially close aromatic Phe124 and Phe24, to the N-terminal helix region with the Met7/Gly11 pair in the “lower right” part of the molecule. B) The IBS residues of AtxA are presented in blue mesh surface (Leu2, Leu3, Leu19, Thr20, Phe24, Val31, Ser67, Lys69, Thr70, Arg72, Arg118, Asn119 and Phe124) and surround the active site pocket with His48 and Asp99 (presented in green). C) The Atx–CaM interaction surface comprises most of the C-terminal residues of AtxA in the region 108–131 and several basic residues in α -helices C and D (red mesh surface representation; more details in Kovačič et al., 2010). D) The anticoagulant activity of AtxA is a consequence of its binding to factor Xa, which involves mostly basic residues (magenta mesh surface): Arg118, Lys127, Lys128 and Lys132 in the C-terminal end and Arg72, Lys74, His74 and Arg77 in the β -structure region (Prijatelj et al., 2006a).

Ca²⁺ cofactor, which is coordinatively bound by three main-chain carbonyl oxygen atoms of residues in the conserved Ca²⁺-binding loop of the enzyme (Tyr28, Gly30 and Gly32) by two carboxylate oxygen atoms of Asp49, and by two oxygen atoms from the phospholipid substrate (Scott et al., 1990). Calcium ion is required for the initial binding of a phospholipid molecule to the active site of sPLA₂s and for the catalytic step, but it is not necessary for adsorption of sPLA₂s to the membrane (Yu et al., 1993). Given that the binding of sPLA₂s to a membrane surface is structurally and kinetically independent of the subsequent binding

and catalytic steps at the active site (Berg et al., 2001), the term substrate specificity in the case of sPLA₂s is a combination of two independent "specificities": (1) the affinity of the enzyme for binding to a membrane surface, governed by the interaction of the IBS and 20–40 phospholipids on the surface, and (2) the relative velocity of hydrolysis of different phospholipid species by the membrane-bound enzyme that obeys Michaelis-Menten kinetics (Berg et al., 2001; Lambeau & Gelb, 2008). The latter is determined by many factors influencing the interactions of the substrate molecule in the active site cleft, the rate of the catalytic reaction and the rate of release of the reaction products. In general, the active sites of sPLA₂s display low specificity for different phospholipid head-groups and acyl chains (Singer et al., 2002). As a consequence, the physiological functions of some sPLA₂s, e.g., the human group IIA (hGIIA), V (hGV) and X (hGX) enzymes, are significantly influenced or even determined by their different interfacial binding specificities and not by the specificity of their catalytic sites (Beers et al., 2003; Bezzine et al., 2000, 2002; Pan et al., 2002; Singer et al., 2002). Therefore, factors influencing interfacial binding of mammalian and toxic sPLA₂s, such as the composition and physical properties of the membrane, the nature of the IBS of the enzyme, and the concentration of phospholipids that are accessible to the sPLA₂ (Mounier et al., 2004), are crucial determinants of sPLA₂ biological activity.

The IBS of most sPLA₂s comprises a ring of conserved hydrophobic residues, whereas, around them and on the edges of the IBS, some polar, basic and acidic residues are present (Petan et al., 2005; Snitko et al., 1997). Given that most sPLA₂s have high activities on anionic membrane surfaces, it was long thought that electrostatic forces between cationic residues of the enzyme and anionic membrane phospholipids are crucial for the membrane binding and activity of sPLA₂s (Scott et al., 1994). However, a number of studies have shown that, in fact, hydrophobic, aromatic and hydrogen-bonding interactions account for most of the binding energy, even to negatively charged membrane surfaces (Gelb et al., 1999; Ghomashchi et al., 1998; Lin et al., 1998). Nevertheless, it has been suggested that electrostatic interactions are responsible for proper orientation and initial association of sPLA₂s with both anionic and zwitterionic membranes. They may significantly modulate the dynamics of establishing strong hydrophobic interactions, when aliphatic and aromatic residues on the IBS penetrate the membrane surface, needed to form a stable sPLA₂-membrane complex (Beers et al., 2003; Petan et al., 2005; Prijatelj et al., 2008; Stahelin and Cho, 2001).

4.1 Basic structural, interfacial kinetic and binding properties of Atxs

Atxs are highly basic proteins (AtxA has a pI of 10.2, net charge +6), with structural features typical of group IIA sPLA₂ enzymes (Figure 2, A): an N-terminal α -helix A (residues 1–14), a short α -helix B (residues 16–22), a Ca²⁺-binding loop (residues 25–35), a long α -helix C (residues 39–57), a loop preceding an antiparallel two-stranded β -sheet (β -structure; residues 75–78 and 81–84), a long α -helix D (antiparallel to helix C; residues 89–109) and a C-terminal extension (mostly disordered, with two short helical turns; residues 110–133). The active site cleft is buried at the end of a hydrophobic channel (formed by the residues Phe5, Gly6, Tyr22, Ser23, Cys29, Gly30, Ala102, Ala103, Phe106) leading to the highly conserved His48-Asp99 dyad located between the antiparallel α -helices C and D. The entrance to the catalytic site of all sPLA₂s is surrounded by the IBS group of residues, forming a relatively flat surface on one side of the molecule that is responsible for membrane binding – the first and prerequisite step in sPLA₂ catalytic action. The IBS of Atxs (Figure 2, B) is formed by Leu2, Leu3, Leu19, Thr20, Phe24, Val31, Ser67, Lys69, Thr70,

Arg72, Arg118, Asn119, and Phe124 (Petan et al., 2005). The slight structural flexibility observed for the exposed side chains of residues in the IBS (e.g., Phe24 in Figure 2, B) is in keeping with the role of these residues in supporting optimal interactions of the molecule with the dynamic structure of phospholipid aggregates (Saul et al., 2010).

According to the enzymatic activities and membrane-binding affinities of Atxs determined on different phospholipid vesicles, it is clear that these snake venom sPLA₂s are very effective in binding to and hydrolyzing different phospholipid membranes (Petan et al., 2005). This property exists despite the fact that they have evolved to be specific and potent neurotoxic molecules and despite the fact that they share striking structural and functional similarities with the mammalian (non-toxic) sPLA₂s. The enzymatic activities of Atxs on vesicles composed of anionic phosphatidylglycerol (PG), which is, in general, the best sPLA₂ substrate, are comparable to those displayed by the most potent mammalian sPLA₂, the pancreatic group IB sPLA₂, and 5-fold higher than those displayed by the mammalian group IIA sPLA₂s on these vesicles (Singer et al., 2002). Atxs also have particularly high activities on phosphatidylserine (PS) vesicles, the main anionic phospholipid in eukaryotic membranes, well above the activities of the group IB and IIA sPLA₂s that are the most active mammalian sPLA₂s on these vesicles. Most importantly, the activities of Atxs were high also on pure zwitterionic phosphatidylcholine (PC) vesicles, much higher than that of the highly homologous and cationic hGIIA enzyme, which cannot bind to the PC-rich plasma membranes of mammalian cells (Beers et al., 2003; Bezzine et al., 2000, 2002; Birts et al., 2009; Singer et al., 2002). The hGIIA sPLA₂ is well known for its preference for anionic phospholipid substrates and its negligible activity on PC-rich membrane surfaces (Beers et al., 2003; Bezzine et al., 2000, 2002). These properties strongly influence the physiological role of the hGIIA enzyme, for example, by enabling its high antibacterial concentrations in human tears without affecting the corneal epithelial cells (Birts et al., 2009). Although the activities of Atxs were lower than those displayed by group V and X sPLA₂s, which are by far the most potent among the mammalian sPLA₂s in hydrolyzing PC vesicles and releasing fatty acids from cell membranes (Bezzine et al., 2000, 2002; Singer et al., 2002), they were able to hydrolyze plasma membranes of different intact mammalian cells at a rate that correlated well with their specific activities on PC vesicles (Petan et al., 2005; Pražnikar et al., 2008). The high activity of Atxs on PC-rich vesicles is a consequence of the ability of these venom sPLA₂s to bind well to such membrane surfaces, with affinities comparable to those of mammalian group V and X sPLA₂s. Furthermore, unlike the neutral hGX and similarly to the highly cationic hGIIA enzyme, the presence of anionic phospholipids in the membrane surface greatly enhances the membrane-binding affinity of Atxs and consequently the rate of phospholipid hydrolysis (Bezzine et al., 2000, 2002; Petan et al., 2005, 2007). This property may have an important influence on both localization of the toxin to its target membrane and its enzymatic effectiveness *in vivo*. It is now clear that, when conditions of high affinity binding apply (i.e., binding of hGIIA or Atxs to anionic PG vesicles), sPLA₂s reach their half-maximal enzymatic activities at low micromolar concentrations of Ca²⁺ (Petan et al., 2005; Singer et al., 2002). The proposed cytosolic action of Atxs (Pražnikar et al., 2008), and most probably other structurally similar sPLA₂s, is strongly supported by several factors. They may enable the enzymatic activity of Atxs in a reducing environment containing insufficient (nanomolar) concentrations of calcium. In support of this idea are (1) the high degree of stability of AtxA under conditions resembling those in the cytosol of eukaryotic cells (Kovačič et al., 2009; Petrovič et al., 2004), (2) the additional and very significant structural

stabilization and augmentation of sPLA₂ enzymatic activity by CaM (Kovačič et al., 2009, 2010), (3) the transient cytosolic microdomains of high local calcium concentrations (~100 μ M) (Meldolesi et al., 2002) or calcium entry through the damaged plasmalemma due to sPLA₂ action prior to internalization (Montecucco et al., 2008), and (4) the presence of anionic phospholipids (PS) on the cytosolic face of the plasma membrane and internal cellular organelles (Okeley & Gelb, 2004). In conclusion, Atxs are effective enzymes that bind strongly to and hydrolyze rapidly both anionic and zwitterionic phospholipid aggregates, including mammalian plasma membranes, presenting a broad combination of properties characteristic of different mammalian sPLA₂s. The potential for the high enzymatic activity of Atxs appears to be at odds with their specific neurotoxic action. However, it is in line with the possible limitations imposed on their intracellular activity on a particular target membrane by the harsh conditions in the cytosol during the process of neuromuscular transmission blockade.

4.2 Role of different IBS residues in supporting interfacial binding and activity of Atxs

The presence of tryptophan on the IBS of different sPLA₂s is a well-known determinant of their ability to bind with high affinity and hydrolyze PC-rich membranes, crucially influencing their biological roles. Its role has been highlighted in the cases of the hGV and hGX enzymes (Bezzine et al., 2002; Han et al., 1999), the acidic sPLA₂ from *Naja naja atra* snake venom (Sumandea et al., 1999), a range of mutants of hGIIA (Beers et al., 2003) and the pancreatic group IB sPLA₂s (Lee et al., 1996). Despite the fact that Atxs do not contain a Trp residue, they display a relatively high activity on PC vesicles. Furthermore, the substitution of Val31 by Trp led to a dramatic 27-fold increase in the activity of AtxA (Petan et al., 2005), reaching a level of activity on PC-rich vesicles higher than those of hGV and hGX and in the range of the best-acting snake venom sPLA₂s, e.g., the cobra venom sPLA₂ (Sumandea et al., 1999). However, despite its very high affinity for PC-rich surfaces and its order of magnitude higher potency in releasing fatty acids from plasma membranes of intact HEK293 cells, C2C12 myocytes and motoneuronal NSC34 cells (Pražnikar et al., 2008), the AtxA-V31W mutant did not display a major change in neurotoxic potency *in vivo*. This again highlights the dependence of the toxicity of sPLA₂ β -ntxs on a combination of toxin-acceptor interactions leading to localization of the toxin to the target membrane at which the enzymatic activity of AtxA is sufficient for the observed effects. In contrast, the same substitution, V31W, on the IBS of the enzymatically active quaternary mutant AtnL^{YVGD} of the myotoxic Atx homologue, AtnL (see below), caused a 100-fold increase in its activity on PC vesicles, as well as a significant increase in its toxicity *in vivo* and *in vitro* (Petan et al., 2007). Thus, in the case of the enzymatically active mutants of AtnL, the correlation between enzymatic activity on PC membranes and toxicity *in vivo* suggests that the mechanism of their toxicity differs from that used by Atxs and that it depends largely on their interfacial binding affinity and enzymatic activity on PC-rich target membranes, both of which are significantly affected by Trp31 (Petan et al., 2007).

The role of aromatic residues in the interfacial binding of sPLA₂s depends to a high degree on the nature of the residue itself, its position on the IBS and the orientation of its side-chain (Stahelin & Cho, 2001; Sumandea et al., 1999). This is evident from the fact that the substitution of Phe24 with Trp did not cause a substantial increase in enzymatic activity or interfacial binding affinity of AtxA (Petan et al., 2002, 2005) or hGIIA (Beers et al., 2003).

Thus, both Phe and Trp can have similar roles in interfacial binding, despite the differences in their interactions with the membrane: the highly amphiphilic Trp favours partitioning in the interfacial phospholipid head group region of the bilayer (Yau et al., 1998), while the aromatic Phe penetrates deeper into the hydrophobic core of the phospholipid acyl chains (Stahelin & Cho, 2001; Sumandea et al., 1999). In the case of AtxA and hGIIA, Trp31 is obviously in a much better position to influence interfacial binding than is Trp24. Additionally, AtxA and AtxA^{F24W} display higher activities and binding affinities than do the F24S, F24Y and F24N mutants on PC-rich vesicles containing anionic phospholipids. Although the structures of Trp and Phe differ significantly, both are obviously better suited to take advantage of the presence of anionic phospholipid in the interface than the polar Ser, Asn and even the aromatic Tyr. The importance of non-polar interactions in interfacial binding to negatively charged surfaces is also clear in the case of AtxB, AtxA^{KKML} and AtxA^{V31W}. These molecules already display very high activities on PC vesicles containing 10% PS (10% PS/PC vesicles), and they reach the level of maximal activity already on 30% PS/PC vesicles, indicating that the enzymes are fully bound to these vesicles (Petan et al., 2005). In general, we have observed the greatest increases in activity upon introduction of 10% anionic phospholipids (PS or PG) into PC vesicles for mutants that have numbers of hydrophobic and aromatic residues on their IBS similar to or higher than those in AtxA. Besides providing the basis for electrostatic interactions, the presence of anionic phospholipids in PC vesicles may facilitate non-polar interactions as a result of membrane perturbation (Buckland & Wilton, 2000).

Despite the remarkable impact of Trp at position 31 on interfacial binding of Atxs and other sPLA₂s, such as hGIIA (Beers et al., 2003), our subsequent site-directed mutagenesis studies revealed that the positive influence of Trp on membrane binding of sPLA₂s may be significantly diminished, depending on the delicate balance of contributions of each IBS residue to interfacial binding. While Atxs and hGIIA sPLA₂ do not contain a Trp on their IBS, DPLA₂, a weakly neurotoxic sPLA₂ from Russell's viper that differs from AtxA in only 22 residues, has a Trp residue at position 31 and yet displays interfacial binding and kinetic properties similar to those of AtxA (Petan et al., 2005; Prijatelj et al., 2003, 2008). Besides V31W, DPLA₂ contains several other substitutions of equivalent AtxA IBS residues: L19I, T20P, F24S, S67N, T70S, R118M and N119L (Petan et al., 2005; Prijatelj et al., 2008). By analysing the properties of a range of AtxA/DPLA₂ mutants and chimeras (Prijatelj et al., 2008), we were able to pinpoint the IBS residues that are crucial for the intriguing differences in interfacial binding and activity of AtxA and DPLA₂. Not surprisingly, the introduction of Trp31 to the AtxA/DPLA₂^{YIRN} chimera (see Figure 1 for sequence data) caused a very significant 50-fold increase in the rate of hydrolysis of PC vesicles. However, the impact of the same Trp residue, when introduced along with two additional substitutions, producing the AtxA^{KEW}/DPLA₂^{YIRN} mutant, was almost completely abolished, resulting in a low level of activity on PC vesicles, only 2 to 4-fold higher than those of AtxA/DPLA₂^{YIRN}, AtxA and DPLA₂. These results clearly confirmed our earlier suggestion (Petan et al., 2005) that the well-known positive impact of Trp31 on the interfacial binding and enzymatic activity of mammalian and venom sPLA₂s is, to a large extent, counterbalanced by the presence of Lys7 and Glu11 on the edges of the IBS in the case of DPLA₂, instead of the hydrophobic Met7 and nonpolar Gly11 in AtxA. This is most probably a consequence of altered orientation of DPLA₂ on the membrane, due to strong electrostatic interactions between Lys7 and Glu11 and the zwitterionic membrane surface,

which prevents the productive interaction of Trp31, and thus DPLA₂, with the interface. Similarly, two basic residues at nearly equivalent positions in the hGIIA enzyme, Arg7 and Lys10, were shown to have a negative influence on interfacial binding (Bezzine et al., 2002; Snitko et al., 1997). In agreement with this, we have shown that the substitution of Arg at position 72 of the IBS of Atxs and DPLA₂ has a positive impact on interfacial binding and activity only upon introduction of a hydrophobic (Ile), but not a polar (Ser), acidic (Glu) or other basic (Lys) residue (Ivanovski et al., 2004). An additional, albeit smaller, negative effect on interfacial binding and enzymatic activity of DPLA₂ is provided by the presence of the polar residue Ser24 instead of the aromatic and hydrophobic Phe in AtxA (Petan et al., 2002, 2005). However, there are several residues on the IBS of DPLA₂, but not Atxs, that significantly improve its interfacial binding and activity. The YIRN cluster in the C-terminal part of AtxA, shown to be important for its neurotoxic effect (Ivanovski et al., 2000), contains the hydrophilic IBS residues Arg118 and Asn119, while the hydrophobic Tyr115 and Ile116 are not part of the presumed IBS. The introduction of the YIRN cluster into DPLA₂, instead of its KKML cluster, or into the various AtxA/DPLA₂ variants, resulted in a substantial decrease of the initial rates of hydrolysis of charge-neutral PC vesicles (Table 2). Therefore, the presence of a hydrophobic or aromatic IBS residue at positions 118 and 119 has a significant positive influence on interfacial binding to anionic and, particularly, zwitterionic phospholipid surfaces. Accordingly, this positive impact is evident in the case of Met118 and Leu119 in DPLA₂ and the AtxA^{KKML} mutant, as well as of Met118 and Tyr119 in AtxB, in contrast to the hydrophilic Arg118 and Asn119 in AtxA and mutants containing the YIRN cluster (Ivanovski et al., 2000; Petan et al., 2005; Prijatelj et al., 2003, 2008). Considering the similar activities on PC-rich vesicles displayed by AtxB and the AtxA^{KKML} mutant, it is obvious that the roles of Tyr and Leu at position 119 are in fact very similar. This indicates that the removal of the polar cluster Arg118/Asn119 from AtxA has a greater positive effect on interfacial binding than the aromatic or hydrophobic nature of the substituting residue at position 119, which is in accordance with the negligible impact of the substitution Y119W on interfacial binding of hGIIA sPLA₂ to 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) vesicles (Beers et al., 2003). Thus, the role of aromatic residues, including Trp, in interfacial binding of sPLA₂s, depends strongly, as well as on their nature, position on the IBS, and side-chain orientation, on the counterbalancing effects of polar/electrostatic interactions provided by hydrophilic/charged residues on or near the IBS. In conclusion, the most significant differences in interfacial binding and enzymatic activity of AtxA and DPLA₂ are therefore a consequence of the natural substitutions that have led to significant changes in the hydrophobic/aromatic character of residues on or near the IBS – M7K, G11E, F24S, V31W, R118M and N119L.

5. Interaction of Atxs with high-affinity binding proteins

Several high-affinity binding proteins for Atxs have been identified in porcine cerebral cortex. Two of these are membrane proteins of 25 kDa (R25) and 180 kDa (R180). R25, which is located in the mitochondrial membrane (Šribar et al., 2003a), binds only Atxs (Vučemilo et al., 1998), whereas R180, identified as the plasma membrane M-type sPLA₂ receptor (sPLA₂R), binds both toxic and non-toxic sPLA₂s of groups IB and IIA (Čopić et al., 1999; Vardjan et al., 2001). Surprisingly, several cytosolic, high-affinity binding proteins for Atxs were identified as well – calmodulin (CaM) (Šribar et al., 2001), the γ and

sPLA ₂	Specific activity ($\mu\text{mol}/(\text{min} \times \text{mg})$)				
	POPG	POPS	POPC	10% POPS/POPC	30% POPS/POPC
AtxA	1042 $\pm$ 160	1251 $\pm$ 188	3.8 $\pm$ 0.5	56 $\pm$ 6	450 $\pm$ 21
AtxB	1149 $\pm$ 34	1189 $\pm$ 153	14 $\pm$ 2	240 $\pm$ 22	1133 $\pm$ 150
AtxC	1116 $\pm$ 91	477 $\pm$ 101	1.9 $\pm$ 0.2	14.0 $\pm$ 1.3	166 $\pm$ 21
AtnI ₂	1070 $\pm$ 150	57 $\pm$ 5	12.3 $\pm$ 1.7	49 $\pm$ 2	159 $\pm$ 16
AtxA ^{KKML}	1148 $\pm$ 126	1252 $\pm$ 40	19 $\pm$ 1	400 $\pm$ 22	1322 $\pm$ 42
AtxA ^{V31W}	2102 $\pm$ 88	1964 $\pm$ 154	102 $\pm$ 7	525 $\pm$ 28	1957 $\pm$ 36
AtxA ^{F24W}	914 $\pm$ 43	906 $\pm$ 56	4.4 $\pm$ 0.5	50 $\pm$ 1	209 $\pm$ 6
AtxA ^{F24Y}	822 $\pm$ 41	1304 $\pm$ 102	2.1 $\pm$ 0.1	9.5 $\pm$ 0.5	163 $\pm$ 11
AtxA ^{F24N}	780 $\pm$ 29	535 $\pm$ 43	1.09 $\pm$ 0.03	5.1 $\pm$ 0.5	68 $\pm$ 3
AtxA ^{F24A}	813 $\pm$ 107	1291 $\pm$ 65	1.2 $\pm$ 0.1	4.4 $\pm$ 0.3	92 $\pm$ 5
AtxA ^{F24S}	400 $\pm$ 73	430 $\pm$ 42	0.71 $\pm$ 0.06	4.4 $\pm$ 0.1	24 $\pm$ 4
AtxA ^{R72E}	438 $\pm$ 26	n. d.	0.33 $\pm$ 0.07	n. d.	n. d.
AtxA ^{R72I}	1655 $\pm$ 108	n. d.	6.9 $\pm$ 0.8	n. d.	n. d.
AtxA ^{R72K}	686 $\pm$ 102	n. d.	1.2 $\pm$ 0.1	n. d.	n. d.
AtxA ^{R72S}	800 $\pm$ 82	n. d.	1.6 $\pm$ 0.3	n. d.	n. d.
DPLA ₂	1600 $\pm$ 130	1195 $\pm$ 47	1.1 $\pm$ 0.1	88 $\pm$ 9	442 $\pm$ 31
DPLA ₂ ^{YIRN}	1100 $\pm$ 120	996 $\pm$ 129	0.07 $\pm$ 0.02	4.2 $\pm$ 0.4	141 $\pm$ 20
AtxA/DPLA ₂	1300 $\pm$ 140	n. d.	3.14 $\pm$ 0.05	n. d.	n. d.
AtxA ^{KEW} /DPLA ₂ ^{YIRN}	1200 $\pm$ 170	n. d.	2.2 $\pm$ 0.5	n. d.	n. d.
AtxA ^{KE} /DPLA ₂ ^{YIRN}	830 $\pm$ 80	n. d.	0.14 $\pm$ 0.01	n. d.	n. d.
AtxA ^W /DPLA ₂ ^{YIRN}	1900 $\pm$ 210	n. d.	26 $\pm$ 3	n. d.	n. d.
AtxA/DPLA ₂ ^{YIRN}	1000 $\pm$ 120	n. d.	0.53 $\pm$ 0.06	n. d.	n. d.
AtnL	No activity	No activity	No activity	n. d.	n. d.
AtnL ^{YVGD}	225 $\pm$ 35	91 $\pm$ 7	~0.005	0.49 $\pm$ 0.04	43 $\pm$ 2
AtnL ^{YWGD}	180 $\pm$ 25	89 $\pm$ 10	0.22 $\pm$ 0.03	8.3 $\pm$ 0.3	96 $\pm$ 5
12-AtxA	5.2 $\pm$ 0.7	n. d.	0.76 $\pm$ 0.06	n. d.	n. d.
I-AtxA	4.0 $\pm$ 0.2	n. d.	0.96 $\pm$ 0.04	n. d.	n. d.
P-AtxA	1.29 $\pm$ 0.04	n. d.	0.13 $\pm$ 0.03	n. d.	n. d.
hGIIA	220 $\pm$ 90	40 $\pm$ 18	Lag, 0.7 $\pm$ 0.2	n. d.	n. d.
hGX	14 $\pm$ 0.8	4 $\pm$ 2	30 $\pm$ 0.2	n. d.	n. d.

Table 2. Specific enzymatic activity of sPLA₂s on phospholipid vesicles. The specific enzymatic activities were determined on extruded phospholipid vesicles composed of 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphoserine (POPS), 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphoglycerol (POPG), and on vesicles with mixed compositions as stated (in molar percentage) in the Table. The initial rates of phospholipid hydrolysis were measured using a sensitive fluorescence, fatty acid displacement assay; the enzymatic activities were calculated after calibrating the responses with known amounts of oleic acid (Petan et al., 2005). The enzymatic activity value for each sPLA₂ is the mean $\pm$ S.D. of at least five independent measurements. Data taken from Ivanovski et al. (2004), Petan et al. (2005, 2007), Prijatelj et al. (2006b, 2008), and Singer et al. (2002).

ϵ isoforms of 14-3-3 proteins (Šribar et al., 2003b), and protein disulphide isomerase (Šribar et al., 2005). This suggests the possibility of not only intracellular, but also cytosolic, action of Atxs and other sPLA₂s. They have since been shown to be surprisingly stable in the reducing environment of the eukaryotic cytosol. They are enzymatically active at low micromolar concentrations of Ca²⁺ ions, and they are also structurally stabilized and activated by binding to CaM (Kovačič et al., 2009, 2010; Petan et al., 2005; Petrovič et al.,

2005). Atxs were also found to bind factor Xa (FXa) and display anticoagulant activity (Priatelj et al., 2006a). Given that the topic of neuronal high-affinity binding proteins for Atxs and their putative roles in β -neurotoxicity has been reviewed recently (Pungerčar & Križaj, 2007), here we only summarize the results obtained with a range of Atx mutants for binding to CaM, R25, FXa and the M-type sPLA₂ receptor.

5.1 The C-terminal region of Atxs has a novel calmodulin binding motif

Our protein engineering and competition binding studies using a range of Atxs, DPLA₂ and AtnI₂ mutants and chimeras, as well as synthetic peptides corresponding to different regions of Atxs, ultimately resulted in the identification of a novel binding motif for the ubiquitous, highly conserved Ca²⁺-sensor CaM (Kovačič et al., 2010; Priatelj et al., 2003). The C-terminal region of AtxA, with a distinctive hydrophobic patch within the region 107–125 surrounded by several basic residues, was identified as the most important element for binding to the N-terminal methionine-rich pocket of CaM in its Ca²⁺-induced dumbbell conformation. This work was based on the intriguing 150-fold lower lethal potency and the correspondingly 50-fold lower CaM-binding affinity of DPLA₂ compared to AtxA (Priatelj et al., 2003). Most notably, the DPLA₂^{YIRN} mutant, containing the C-terminal YIRN cluster of AtxA (see above and Figure 1), displayed a 7-fold increase in binding affinity for CaM, only 7-fold lower than that of AtxA. This result suggested a major role of this region for the interaction with CaM. On the other hand, introduction of the whole N-terminal half of AtxA to DPLA₂ and DPLA₂^{YIRN} caused only a slight, 2 to 3-fold increase in binding affinities for CaM, suggesting that the N-terminal part of AtxA has only a supporting role in the binding and is probably located on the periphery of the CaM binding site (Priatelj et al., 2008). Very recently, we confirmed unambiguously the crucial importance of the C-terminal region of Atxs in CaM binding by building several three-dimensional structural models of sPLA₂–CaM complexes, based on AtxA–CaM interaction site mapping, our previous mutagenesis data and protein-docking algorithms (Kovačič et al., 2010). According to the model, the closed conformation of CaM forms a “clamp” around AtxA, with most of the C-terminal residues of AtxA in the region 108–131 being in direct contact with CaM (Figure 2, C). There are only a few additional, but important, contacts between the proteins, formed mainly by basic residues in α -helices C (Arg43 and Asn54) and D (Arg94, Lys108, Asn109 and Lys111) of AtxA. Importantly, the model was validated by superimposing the structures of several mammalian sPLA₂s on that of AtxA in the complex and correctly predicting the favourable interactions of group V and X mammalian sPLA₂s and CaM. The model also showed the basis for the unfavourable interactions, which prevented complex formation between the structurally very similar mammalian group IB and IIA sPLA₂s and CaM. Formation of the complexes was confirmed by competition binding experiments and the augmentation of the enzymatic activity of those sPLA₂s interacting with CaM. Most importantly, we have clearly demonstrated that CaM stabilizes and protects Atxs from denaturation in the reducing environment of the cell cytosol and acts as a non-essential activator of Atxs and of the mammalian group V and X sPLA₂s. The fact that CaM-binding results in stabilization and augmentation of enzymatic activity of sPLA₂s, ranging from the neurotoxic Atxs to the mammalian group V and X sPLA₂s, suggests a novel role for CaM as a regulator of the intracellular actions of some toxic and non-toxic sPLA₂s, which may be active even in the reducing environment of the cytosol (Kovačič et al., 2009, 2010). The significance of CaM–sPLA₂ interactions in the pharmacological and (patho)physiological roles of sPLA₂s remain to be confirmed.

5.2 The N- and C-terminal regions of Atxs are involved in binding to the neuronal M-type sPLA₂ receptor (R180)

The M-type sPLA₂ receptor, which was cloned and revealed as a member of the C-type lectin superfamily, has been well-characterized and is currently the best-known sPLA₂ binding target. It was shown recently that the M-type receptor is involved in regulating cell senescence (Augert et al., 2009) and is the main antigen target in autoimmune human membranous nephropathy (Beck et al., 2009). However, the pathophysiological implications of the interaction between the M-type sPLA₂ receptors and both toxic and non-toxic sPLA₂s in general are intriguing and still unknown (Lambeau & Gelb, 2008; Pungertar & Krizaj, 2007; Rouault et al., 2006). Although it has been suggested that the neuronal M-type sPLA₂ receptor located on the plasma membrane could be responsible for specific targeting and internalization of sPLA₂ neurotoxins in presynaptic nerve terminals, the results of our mutagenesis studies have shown that it may not be involved in the neurotoxicity of Atxs (Priatelj et al., 2006b). In order to prevent the interaction between AtxA and the receptor, we prepared three mutants of AtxA, containing either the 12-amino acid-long peptide ARIRARSGIEGR, named 12-AtxA, or one each of two variants of a shorter 5-amino acid peptide (ASIGQ and ASPGQ; named I-AtxA and P-AtxA, respectively) fused to the N-terminus of AtxA. These peptides are similar to the N-terminal propeptides present in proenzymes of mammalian group IB (e.g., DSGISPR in human pancreatic proPLA₂) and group X sPLA₂s (e.g., EASRILRVHRR in the human proenzyme), which do not bind to the M-type sPLA₂ receptor (Hanasaki & Arita, 2002; Lambeau et al., 1995). The presence of the fusion peptides in AtxA indeed completely abolished the interaction of the toxin with the M-type receptor. However, the mutants displayed only one order of magnitude lower lethality in mice and were able to induce neurotoxic effects on a mouse phrenic nerve-hemidiaphragm preparation (see Table 1). Although the N-terminal fusion peptides acted effectively as “propeptides” for AtxA and lowered specific enzymatic activity to ~1% of the wild-type enzyme, their similar neurotoxic profiles on the neuromuscular junction indicate that minimal enzymatic activity suffices for presynaptic toxicity of sPLA₂s. Additionally, antibodies targeting the sPLA₂-binding C-type lectin-like domain 5 of the M-type sPLA₂ receptor were unable to abolish the neurotoxic action of AtxA on the neuromuscular preparation. Thus, the interaction of AtxA with the neuronal M-type sPLA₂ receptor, R180, is apparently not essential for its presynaptic neurotoxicity. Since we performed the binding experiments with the N-terminal fusion AtxA mutants, using porcine sPLA₂ receptor, the question still remains as to whether the fusion peptides would also abolish the binding of AtxA to the mouse R180 receptor.

Nevertheless, our site-directed mutagenesis studies have provided important information about the parts of the AtxA molecule involved in binding to R180. Interestingly, the C-terminal YIRN cluster, which is essential for neurotoxicity and binding to CaM and R25, appears to be involved in binding to R180 as well. The first clues were provided by the lower affinity of the AtxA^{KKML} mutant and DPLA₂ for binding to R180 (Ivanovski et al., 2000). (Both contain KKML instead of the YIRN cluster.) The higher binding affinity of mutants containing the YIRN cluster (DPLA₂^{YIRN} or AtxA/DPLA₂^{YIRN}) confirmed that it is an important part of the AtxA/R180 interaction surface. However, other parts of the molecule also contribute considerably to the binding affinity of AtxA. Interestingly, the N-terminal part of AtxA in the chimera AtxA/DPLA₂ did not increase the binding affinity of DPLA₂ to R180. However, the introduction of three N-terminal DPLA₂ residues (K, E

and/or W) to AtxA/DPLA₂^{YIRN} caused an increase in the binding affinity for R180 up to the level of AtxA, confirming the expected involvement of the N-terminal part of the molecule in binding to R180 as well. Therefore, the interaction surface of AtxA with its neuronal M-type receptor, R180, extends from the C-terminal top of the molecule, across the area close to the Ca²⁺-binding loop and the IBS, reaching the N-terminal helix on the edges of the IBS.

5.3 Atxs bind to the mitochondrial receptor R25 through their C-terminal region

The C-terminal region of Atxs appears to be essential also for binding to the, as yet unidentified, mitochondrial membrane receptor R25. The affinities for binding of the chimeric mutants to R25 ranged from that of the non-toxic AtnI₂, which does not bind to R25, to those of AtxA, AtnI₂/AtxA^{K108N} and AtnI₂^{N24F}/AtxA^{K108N}, which were similar to that of AtxA (Prijetelj et al., 2002). Additionally, substitutions of Phe24 in the N-terminal part of AtxA had a negligible effect on its affinity for R25, but nevertheless indicated that this residue is in the vicinity of the toxin-receptor binding surface, most probably located in the C-terminal part of AtxA (Petan et al., 2002). Furthermore, while DPLA₂ and the chimera AtxA/DPLA₂ could not completely inhibit the binding of AtxC to R25 in competition binding experiments, the substitution of their KKML cluster with the YIRN cluster led to complete inhibition with a relatively high binding affinity. This implies that residues in the region 115–119 are very important for effective binding to R25, which is apparently present in multiple isoforms. However, the complete inhibition of binding of radiolabelled AtxC to R25 by the AtxA^{KKML} mutant, in contrast to DPLA₂ and AtxA/DPLA₂, indicated that the interaction surface extends beyond the C-terminal region. Indeed there was a slight increase in binding affinity upon introduction of the N-terminal Lys7, Glu11 and/or Trp31 of DPLA₂ to the AtxA/DPLA₂^{YIRN} chimera (K, E and/or W; Table 1). While our site-directed mutagenesis and competition binding studies have so far revealed a central role for the C-terminal residues of Atxs in high affinity binding to R25, the interaction surface probably extends beyond the C-terminal region.

5.4 Atxs exert anticoagulant effects by binding to factor Xa

In the analysis of non-neurotoxic effects of Atxs, our study of an array of site-directed mutants (Prijetelj et al., 2006a) showed that basic residues in the C-terminal and β -structure regions are important for AtxA binding to human blood coagulation factor Xa (Figure 2, D). Hence, AtxA has anticoagulant activity. In addition, the 10-fold lower affinity of AtxC for factor Xa, in comparison with AtxA, is due to the (natural) charge-reversal substitution of Lys128 by Glu, leading to a small local conformational change in the C-terminal end of AtxC, which perturbs the interaction with factor Xa (Saul et al., 2010).

6. Restoration of enzymatic activity reduces the Ca²⁺-independent membrane damage induced by the myotoxic ammodytin L

Ammodytin L (AtnL) is a myotoxic and enzymatically inactive structural homologue of Atxs (Petan et al., 2007; Pungercar et al., 1990). The main structural feature of snake venom sPLA₂-like myotoxins is the substitution of the highly-conserved aspartic acid residue at position 49, effectively preventing Ca²⁺ binding and thus abolishing catalytic

activity (Petan et al., 2007; Ward et al., 2002). The most common substitution is Lys, but AtnL is one of the two known Ser49 sPLA₂ homologues. In addition to this replacement, several other substitutions of highly-conserved residues in the enzymatically inactive sPLA₂s are found concentrated in the region of the Ca²⁺-binding loop, where the carbonyl oxygen atoms of Tyr28, Gly30 and Gly32 provide three additional coordinative bonds for Ca²⁺-binding. The myotoxic activity of the Lys49 sPLA₂s, as well as of the Ser49-containing AtnL, is best characterized by their ability to induce myonecrosis *in vivo* and show a potent Ca²⁺-independent membrane-damaging activity *in vitro* (Lomonte et al., 2009). Although the involvement of a skeletal muscle protein acceptor in the process of sPLA₂-induced myotoxicity cannot be ruled out, a considerable body of evidence has been accumulated indicating that the myotoxic effects are a consequence of a Ca²⁺-independent protein-lipid interaction that causes direct damage of the plasma membrane of target muscle cells and may allow entry of extracellular Ca²⁺ and irreversible cell damage (Cintra-Francischini et al., 2010; Lomonte et al., 2009; Rufini et al., 1992). The calcium-independent, and thus enzymatic activity-independent, mechanism of membrane damage is also supported by experiments in which inhibition of certain enzymatically active Asp49 myotoxic sPLA₂s did not eliminate their myotoxic activity (Soares et al., 2001).

We recently described the first example of restoration of activity in AtnL or in any enzymatically inactive Ser49/Lys49 sPLA₂ homologue (Petan et al., 2007). We prepared two enzymatically active quaternary mutants of AtnL (H28Y/L31V,W/N33G/S49D), differing at position 31. Although Asn33 is not directly involved in Ca²⁺ coordination, we suspected that it might have a negative impact on the optimal local structure of the Ca²⁺-binding loop. We therefore replaced it with a glycine residue, which is very often found at this position in catalytically active sPLA₂s, as well as in Atxs. Val31 was present in the AtnL^{YVGD} mutant in order to recreate the Ca²⁺-binding loop of Atxs, while the AtnL^{YWGD} mutant had Trp31 in order to enhance its membrane binding affinity, and thus enzymatic activity, as previously shown in the case of the AtxA^{V31W} mutant described above. The successful restoration of enzymatic activity by such a small number of substitutions indicates that, apart from the residues involved in Ca²⁺ coordination, the remainder of the substrate-binding and catalytic network of AtnL is very well conserved. Apparently, in evolution, Lys49 and Ser49 sPLA₂ myotoxins have lost their Ca²⁺-binding ability and enzymatic activity through subtle changes in the Ca²⁺-binding network alone, without affecting the rest of the catalytic machinery. Our results strongly suggest that these changes were selected for their Ca²⁺-independent membrane-damaging ability and increase the specificity of their myotoxic activity. Although the restoration of enzymatic activity in AtnL increased its cytotoxic potency and lethality in general, it had a negative effect on its Ca²⁺-independent mechanism of membrane damage and on its ability to specifically target differentiated muscle cells *in vitro*. Given that AtnL shares a high level of identity with AtxA (74%), it was not surprising that the enzymatically active mutants of AtnL displayed a combination of the properties of both toxins. In other words, the restoration of enzymatic activity of AtnL reduced its ability to act as a potent and specific myotoxic molecule. The latter supports the idea of an evolutionary specialization of Ser49/Lys49 sPLA₂ homologues to perform the role of abundant and weakly lethal, but specific, muscle-targeting toxins in the arsenal of pharmacologically active molecules found in snake venom.

7. Future perspectives

Recently, we have been able to introduce a free cysteine residue into the molecule of AtxA by substituting Asn79 by Cys at the turn of the antiparallel β -sheet. This mutation allowed for specific labelling of the neurotoxin molecule by either fluorescent or nanogold probes (Pražnikar et al., 2008, 2009). The conjugates were less toxic than the wild-type toxin, but retained its basic properties. They have proved to be a valuable tool in the study of presynaptic neurotoxicity. As an illustration, we have provided evidence that AtxA, a neurotoxic snake venom sPLA₂, is indeed internalized into mammalian (mouse) motor nerve terminals (Logonder et al., 2009).

We believe that similar approaches can be used in further protein engineering of Atxs and also other β -ntxs, especially in monitoring their trafficking and cellular action (enzymatic activity, binding to protein target molecules). This should finally lead to a complete understanding of the molecular mechanism of presynaptic toxicity of sPLA₂ neurotoxins, which may also open the way for better medical treatment of snake envenomation. Moreover, similar research approaches can also be exploited in the studies of homologous mammalian sPLA₂s whose biological roles are still to be clarified.

8. Acknowledgment

The authors wish to thank Dr Roger H. Pain for critical reading of the manuscript.

9. References

- Augert, A., Payré, C., De Launoit, Y., Gil, J., Lambeau, G. & Bernard, D. (2009). The M-type receptor PLA₂R regulates senescence through the p53 pathway. *EMBO Reports*, Vol. 10, No. 3, pp. 271–277
- Beck, L.H., Bonegio, R.G.B., Lambeau, G., Beck, D.M., Powell, D.W., Cummins, T.D., Klein, J.B. & Salant, D.J. (2009). M-type phospholipase A₂ receptor as target antigen in idiopathic membranous nephropathy. *New England Journal of Medicine*, Vol. 361, No. 1, pp. 11–21
- Beers, S.A., Buckland, A.G., Giles, N., Gelb, M.H. & Wilton, D.C. (2003). Effect of tryptophan insertions on the properties of the human group IIA phospholipase A₂: Mutagenesis produces an enzyme with characteristics similar to those of the human group V phospholipase A₂. *Biochemistry*, Vol. 42, No. 24, pp. 7326–7338
- Berg, O.G., Gelb, M.H., Tsai, M.D. & Jain, M.K. (2001). Interfacial enzymology: The secreted phospholipase A₂-paradigm. *Chemical Reviews*, Vol. 101, No. 9, pp. 2613–2654
- Bezzine, S., Koduri, R.S., Valentin, E., Murakami, M., Kudo, I., Ghomashchi, F., Sadilek, M., Lambeau, G. & Gelb, M.H. (2000). Exogenously added human group X secreted phospholipase A₂ but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. *Journal of Biological Chemistry*, Vol. 275, No. 5, pp. 3179–3191
- Bezzine, S., Bollinger, J.G., Singer, A.G., Veatch, S.L., Keller, S.L. & Gelb, M.H. (2002). On the binding preference of human groups IIA and X phospholipases A₂ for membranes with anionic phospholipids. *Journal of Biological Chemistry*, Vol. 277, No. 50, pp. 48523–48534

- Birts, C.N., Barton, C.H. & Wilton, D.C. (2010). Catalytic and non-catalytic functions of human IIA phospholipase A₂. *Trends in Biochemical Sciences*, Vol. 35, No. 1, pp. 28–35
- Buckland, A.G. & Wilton, D.C. (2000). Anionic phospholipids, interfacial binding and the regulation of cell functions. *Biochimica et Biophysica Acta*, Vol. 1483, No. 2, pp. 199–216
- Cintra-Francischinelli, M., Pizzo, P., Angulo, Y., Gutiérrez, J.M., Montecucco, C. & Lomonte, B. (2010). The C-terminal region of a Lys49 myotoxin mediates Ca²⁺ influx in C2C12 myotubes. *Toxicon*, Vol. 55, No. 2-3, pp. 590–596
- Čopič, A., Vučemilo, N., Gubenšek, F. & Križaj, I. (1999). Identification and purification of a novel receptor for secretory phospholipase A₂ in porcine cerebral cortex. *Journal of Biological Chemistry*, Vol. 274, No. 37, pp. 26315–26320
- Gelb, M.H., Cho, W. & Wilton, D.C. (1999). Interfacial binding of secreted phospholipases A₂: More than electrostatics and a major role for tryptophan. *Current Opinion in Structural Biology*, Vol. 9, No. 4, pp. 428–432
- Ghomashchi, F., Lin, Y., Hixon, M.S., Yu, B.Z., Annand, R., Jain, M.K. & Gelb, M.H. (1998). Interfacial recognition by bee venom phospholipase A₂: Insights into nonelectrostatic molecular determinants by charge reversal mutagenesis. *Biochemistry*, Vol. 37, No. 19, pp. 6697–6710
- Han, S.K., Kim, K.P., Koduri, R., Bittova, L., Munoz, N.M., Leff, A.R., Wilton, D.C., Gelb, M.H. & Cho, W. (1999). Roles of Trp31 in high membrane binding and proinflammatory activity of human group V phospholipase A₂. *Journal of Biological Chemistry*, Vol. 274, No. 17, pp. 11881–11888
- Hanasaki, K. & Arita, H. (2002). Phospholipase A₂ receptor: A regulator of biological functions of secretory phospholipase A₂. *Prostaglandins & Other Lipid Mediators*, Vol. 68–69, pp. 71–82
- Ivanovski, G., Čopič, A., Križaj, I., Gubenšek, F. & Pungerčar, J. (2000). The amino acid region 115–119 of ammodytoxins plays an important role in neurotoxicity. *Biochemical and Biophysical Research Communications*, Vol. 276, No. 3, pp. 1229–1234
- Ivanovski, G., Petan, T., Križaj, I., Gelb, M.H., Gubenšek, F. & Pungerčar, J. (2004). Basic amino acid residues in the β-structure region contribute, but not critically, to presynaptic neurotoxicity of ammodytoxin A. *Biochimica et Biophysica Acta*, Vol. 1702, No. 2, pp. 217–225
- Kini, R.M. & Evans, H.J. (1989). A model to explain the pharmacological effects of snake venom phospholipases A₂. *Toxicon*, Vol. 27, No. 6, pp. 613–635
- Kini, R.M. & Chan, Y.M. (1999). Accelerated evolution and molecular surface of venom phospholipase A₂ enzymes. *Journal of Molecular Evolution*, Vol. 48, No. 2, pp. 125–132
- Kini, R.M. (2003). Excitement ahead: Structure, function and mechanism of snake venom phospholipase A₂ enzymes. *Toxicon*, Vol. 42, No. 8, pp. 827–840
- Kovačič, L., Novinec, M., Petan, T., Baici, A. & Križaj, I. (2009). Calmodulin is a nonessential activator of secretory phospholipase A₂. *Biochemistry*, Vol. 48, No. 47, pp. 11319–11328
- Kovačič, L., Novinec, M., Petan, T. & Križaj, I. (2010). Structural basis of the significant calmodulin-induced increase in the enzymatic activity of secreted phospholipases A₂. *Protein Engineering, Design & Selection*, Vol. 23, No. 6, pp. 479–487
- Križaj, I. (2011). Ammodytoxin: A window into understanding presynaptic toxicity of secreted phospholipases A₂ and more. *Toxicon*, Vol. 58, No. 3, pp. 219–229
- Lambeau, G., Ancian, P., Nicolas, J.P., Beiboer, S.H., Moinier, D., Verheij, H. & Lazdunski, M. (1995). Structural elements of secretory phospholipases A₂ involved in the

- binding to M-type receptors. *Journal of Biological Chemistry*, Vol. 270, No. 10, pp. 5534–5540
- Lambeau, G. & Gelb, M.H. (2008). Biochemistry and physiology of mammalian secreted phospholipases A₂. *Annual Review of Biochemistry*, Vol. 77, pp. 495–520
- Lee, B.I., Yoon, E.T. & Cho, W. (1996). Roles of surface hydrophobic residues in the interfacial catalysis of bovine pancreatic phospholipase A₂. *Biochemistry*, Vol. 35, No. 13, pp. 4231–4240
- Lin, Y., Nielsen, R., Murray, D., Hubbell, W.L., Mailer, C., Robinson, B.H. & Gelb, M.H. (1998). Docking phospholipase A₂ on membranes using electrostatic potential-modulated spin relaxation magnetic resonance. *Science*, Vol. 279, No. 5358, pp. 1925–1929
- Logonder, U., Jenko-Pražnikar, Z., Scott-Davey, T., Pungerčar, J., Križaj, I. & Harris, J.B. (2009). Ultrastructural evidence for the uptake of a neurotoxic snake venom phospholipase A₂ into mammalian motor nerve terminals. *Experimental Neurology*, Vol. 219, No. 2, pp. 591–594
- Lomonte, B., Angulo, Y., Sasa, M. & Gutiérrez, J.M. (2009). The phospholipase A₂ homologues of snake venoms: Biological activities and their possible adaptive roles. *Protein and Peptide Letters*, Vol. 16, No. 8, pp. 860–876
- Meldolesi, J. (2002). Rapidly exchanging Ca²⁺ stores: Ubiquitous partners of surface channels in neurons. *News in Physiological Sciences*, Vol. 17, pp. 144–149
- Montecucco, C., Gutiérrez, J.M. & Lomonte, B. (2008). Cellular pathology induced by snake venom phospholipase A₂ myotoxins and neurotoxins: Common aspects of their mechanisms of action. *Cellular and Molecular Life Sciences*, Vol. 65, No. 18, pp. 2897–2912
- Mounier, C.M., Ghomashchi, F., Lindsay, M.R., James, S., Singer, A.G., Parton, R.G. & Gelb, M.H. (2004). Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A₂ occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A₂-α. *Journal of Biological Chemistry*, Vol. 279, No. 24, pp. 25024–25038
- Murakami, M., Taketomi, Y., Miki, Y., Sato, H., Hirabayashi, T. & Yamamoto, K. (2011). Recent progress in phospholipase A₂ research: From cells to animals to humans. *Progress in Lipid Research*, Vol. 50, No. 2, pp. 152–192
- Okeley, N.M. & Gelb, M.H. (2004). A designed probe for acidic phospholipids reveals the unique enriched anionic character of the cytosolic face of the mammalian plasma membrane. *Journal of Biological Chemistry*, Vol. 279, No. 21, pp. 21833–21840
- Pan, Y.H., Yu, B.-Z., Singer, A.G., Ghomashchi, F., Lambeau, G., Gelb, M.H., Jain, M.K. & Bahnson, B.J. (2002). Crystal structure of human group X secreted phospholipase A₂. Electrostatically neutral interfacial surface targets zwitterionic membranes. *Journal of Biological Chemistry*, Vol. 277, No. 32, pp. 29086–29093
- Paoli, M., Rigoni, M., Koster, G., Rossetto, O., Montecucco, C. & Postle, A.D. (2009). Mass spectrometry analysis of the phospholipase A₂ activity of snake pre-synaptic neurotoxins in cultured neurons. *Journal of Neurochemistry*, Vol. 111, No. 3, pp. 737–744
- Petan, T., Križaj, I., Gubenšek, F. & Pungerčar, J. (2002). Phenylalanine-24 in the N-terminal region of ammodytoxins is important for both enzymic activity and presynaptic toxicity. *Biochemical Journal*, Vol. 363, Pt. 2, pp. 353–358
- Petan, T., Križaj, I., Gelb, M.H. & Pungerčar, J. (2005). Ammodytoxins, potent presynaptic neurotoxins, are also highly efficient phospholipase A₂ enzymes. *Biochemistry*, Vol. 44, No. 37, pp. 12535–12545

- Petan, T., Križaj, I. & Pungerčar, J. (2007). Restoration of enzymatic activity in a Ser-49 phospholipase A₂ homologue decreases its Ca²⁺-independent membrane-damaging activity and increases its toxicity. *Biochemistry*, Vol. 46, No. 44, pp. 12795–12809
- Petrovič, U., Šribar, J., Pariš, A., Rupnik, M., Kržan, M., Vardjan, N., Gubenšek, F., Zorec, R. & Križaj, I. (2004). Ammodytoxin, a neurotoxic secreted phospholipase A₂, can act in the cytosol of the nerve cell. *Biochemical and Biophysical Research Communications*, Vol. 324, No. 3, pp. 981–985
- Petrovič, U., Šribar, J., Matis, M., Anderluh, G., Peter-Katalinić, J., Križaj, I. & Gubenšek, F. (2005). Ammodytoxin, a secretory phospholipase A₂, inhibits G2 cell-cycle arrest in the yeast *Saccharomyces cerevisiae*. *Biochemical Journal*, Vol. 391, Pt. 2, pp. 383–388
- Pražnikar, Z.J., Kovačič, L., Rowan, E.G., Romih, R., Rusmini, P., Poletti, A., Križaj, I. & Pungerčar, J. (2008). A presynaptically toxic secreted phospholipase A₂ is internalized into motoneuron-like cells where it is rapidly translocated into the cytosol. *Biochimica et Biophysica Acta*, Vol. 1783, No. 6, pp. 1129–1139
- Pražnikar, Z.J., Petan, T. & Pungerčar, J. (2009). A neurotoxic secretory phospholipase A₂ induces apoptosis in motoneuron-like cells. *Annals of the New York Academy of Sciences*, Vol. 1152, pp. 215–224
- Prijatelj, P., Čopič, A., Križaj, I., Gubenšek, F. & Pungerčar, J. (2000). Charge reversal of ammodytoxin A, a phospholipase A₂-toxin, does not abolish its neurotoxicity. *Biochemical Journal*, Vol. 352, Pt. 2, pp. 251–255
- Prijatelj, P., Križaj, I., Kralj, B., Gubenšek, F. & Pungerčar, J. (2002). The C-terminal region of ammodytoxins is important but not sufficient for neurotoxicity. *European Journal of Biochemistry*, Vol. 269, No. 23, pp. 5759–5764
- Prijatelj, P., Šribar, J., Ivanovski, G., Križaj, I., Gubenšek, F. & Pungerčar, J. (2003). Identification of a novel binding site for calmodulin in ammodytoxin A, a neurotoxic group IIA phospholipase A₂. *European Journal of Biochemistry*, Vol. 270, No. 14, pp. 3018–3025
- Prijatelj, P., Charnay, M., Ivanovski, G., Jenko, Z., Pungerčar, J., Križaj, I. & Faure, G. (2006a). The C-terminal and β-wing regions of ammodytoxin A, a neurotoxic phospholipase A₂ from *Vipera ammodytes ammodytes*, are critical for binding to factor Xa and for anticoagulant effect. *Biochimie*, Vol. 88, No. 1, pp. 69–76
- Prijatelj, P., Vardjan, N., Rowan, E.G., Križaj, I. & Pungerčar, J. (2006b). Binding to the high-affinity M-type receptor for secreted phospholipases A₂ is not obligatory for the presynaptic neurotoxicity of ammodytoxin A. *Biochimie*, Vol. 88, No. 10, pp. 1425–1433
- Prijatelj, P., Jenko Pražnikar, Z., Petan, T., Križaj, I. & Pungerčar, J. (2008). Mapping the structural determinants of presynaptic neurotoxicity of snake venom phospholipases A₂. *Toxicon*, Vol. 51, No. 8, pp. 1520–1529
- Pungerčar, J., Liang, N.S., Štrukelj, B. & Gubenšek, F. (1990). Nucleotide sequence of a cDNA encoding ammodytin L. *Nucleic Acids Research*, Vol. 18, No. 15, p. 4601
- Pungerčar, J., Križaj, I., Liang, N.S. & Gubenšek, F. (1999). An aromatic, but not a basic, residue is involved in the toxicity of group-II phospholipase A₂ neurotoxins. *Biochemical Journal*, Vol. 341, Pt. 1, pp. 139–145
- Pungerčar, J. & Križaj, I. (2007). Understanding the molecular mechanism underlying the presynaptic toxicity of secreted phospholipases A₂. *Toxicon*, Vol. 50, No. 7, pp. 871–892
- Ramirez, F. & Jain, M.K. (1991). Phospholipase A₂ at the bilayer interface. *Proteins: Structure, Function, and Bioinformatics*, Vol. 9, No. 4, pp. 229–239

- Renetseder, R., Brunie, S., Dijkstra, B.W., Drenth, J. & Sigler, P.B. (1985). A comparison of the crystal structures of phospholipase A₂ from bovine pancreas and *Crotalus atrox* venom. *Journal of Biological Chemistry*, Vol. 260, No. 21, pp. 11627–11634
- Rigoni, M., Caccin, P., Gschmeissner, S., Koster, G., Postle, A.D., Rossetto, O., Schiavo, G. & Montecucco, C. (2005). Equivalent effects of snake PLA₂ neurotoxins and lysophospholipid-fatty acid mixtures. *Science*, Vol. 310, No. 5754, pp. 1678–1680
- Rigoni, M., Paoli, M., Milanese, E., Caccin, P., Rasola, A., Bernardi, P. & Montecucco, C. (2008). Snake phospholipase A₂ neurotoxins enter neurons, bind specifically to mitochondria, and open their transition pores. *Journal of Biological Chemistry*, Vol. 283, No. 49, pp. 34013–34020
- Rosenberg, P. (1997) Pitfalls to avoid in the study of correlations between enzymatic activity and pharmacological properties of phospholipase A₂ enzymes, In: *Venom Phospholipase A₂ Enzymes: Structure, Function and Mechanism* (Kini, R. M., Ed.), pp. 155–183, John Wiley & Sons, Chichester, England.
- Rouault, M., Rash, L.D., Escoubas, P., Boilard, E., Bollinger, J., Lomonte, B., Maurin, T., Guillaume, C., Canaan, S., Dregnaucourt, C., Schrével, J., Doglio, A., Gutiérrez, J.M., Lazdunski, M., Gelb, M.H. & Lambeau, G. (2006). Neurotoxicity and other pharmacological activities of the snake venom phospholipase A₂ OS₂: The N-terminal region is more important than enzymatic activity. *Biochemistry*, Vol. 45, No. 18, pp. 5800–5816
- Rufini, S., Cesaroni, P., Desideri, A., Farias, R., Gubenšek, F., Gutiérrez, J.M., Luly, P., Massoud, R., Morero, R. & Pedersen, J.Z. (1992). Calcium ion independent membrane leakage induced by phospholipase-like myotoxins. *Biochemistry*, Vol. 31, No. 49, pp. 12424–12430
- Saul, F.A., Prijatelj-Žnidaršič, P., Vulliez-le Normand, B., Villette, B., Raynal, B., Pungerčar, J., Križaj, I. & Faure, G. (2010). Comparative structural studies of two natural isoforms of ammodytoxin, phospholipases A₂ from *Vipera ammodytes ammodytes* which differ in neurotoxicity and anticoagulant activity. *Journal of Structural Biology*, Vol. 169, No. 3, pp. 360–369
- Scott, D.L., White, S.P., Otwinowski, Z., Yuan, W., Gelb, M.H. & Sigler, P.B. (1990). Interfacial catalysis: The mechanism of phospholipase A₂. *Science*, Vol. 250, No. 4987, pp. 1541–1546
- Scott, D.L., Mandel, A.M., Sigler, P.B. & Honig, B. (1994). The electrostatic basis for the interfacial binding of secretory phospholipases A₂. *Biophysical Journal*, Vol. 67, No. 2, pp. 493–504
- Singer, A.G., Ghomashchi, F., Le Calvez, C., Bollinger, J., Bezzine, S., Rouault, M., Sadilek, M., Nguyen, E., Lazdunski, M., Lambeau, G. & Gelb, M.H. (2002). Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A₂. *Journal of Biological Chemistry*, Vol. 277, No. 50, pp. 48535–48549
- Snitko, Y., Koduri, R.S., Han, S.K., Othman, R., Baker, S.F., Molini, B.J., Wilton, D.C., Gelb, M.H. & Cho, W. (1997). Mapping the interfacial binding surface of human secretory group IIa phospholipase A₂. *Biochemistry*, Vol. 36, No. 47, pp. 14325–14333
- Soares, A.M., Andrião-Escarso, S.H., Bortoleto, R.K., Rodrigues-Simioni, L., Arni, R.K., Ward, R.J., Gutiérrez, J.M. & Giglio, J.R. (2001). Dissociation of enzymatic and pharmacological properties of piratoxins-I and -III, two myotoxic phospholipases A₂ from *Bothrops pirajai* snake venom. *Archives of Biochemistry and Biophysics*, Vol. 387, No. 2, pp. 188–196

- Šribar, J., Čopič, A., Pariš, A., Sherman, N.E., Gubenšek, F., Fox, J.W. & Križaj, I. (2001). A high affinity acceptor for phospholipase A₂ with neurotoxic activity is a calmodulin. *Journal of Biological Chemistry*, Vol. 276, No. 16, pp. 12493–12496
- Šribar, J., Čopič, A., Poljšak-Prijatelj, M., Kuret, J., Logonder, U., Gubenšek, F. & Križaj, I. (2003a). R25 is an intracellular membrane receptor for a snake venom secretory phospholipase A₂. *FEBS Letters*, Vol. 553, No. 3, pp. 309–314
- Šribar, J., Sherman, N.E., Prijatelj, P., Faure, G., Gubenšek, F., Fox, J.W., Aitken, A., Pungerčar, J. & Križaj, I. (2003b). The neurotoxic phospholipase A₂ associates, through a non-phosphorylated binding motif, with 14-3-3 protein γ and ϵ isoforms. *Biochemical and Biophysical Research Communications*, Vol. 302, No. 4, pp. 691–696
- Šribar, J., Anderluh, G., Fox, J.W. & Križaj, I. (2005). Protein disulphide isomerase binds ammodytoxin strongly: Possible implications for toxin trafficking. *Biochemical and Biophysical Research Communications*, Vol. 329, No. 2, pp. 733–737
- Stahelin, R.V. & Cho, W. (2001). Differential roles of ionic, aliphatic, and aromatic residues in membrane-protein interactions: A surface plasmon resonance study on phospholipases A₂. *Biochemistry*, Vol. 40, No. 15, pp. 4672–4678
- Sumandea, M., Das, S., Sumandea, C. & Cho, W. (1999). Roles of aromatic residues in high interfacial activity of *Naja naja atra* phospholipase A₂. *Biochemistry*, Vol. 38, No. 49, pp. 16290–16297
- Thouin, L.G., Ritonja, A., Gubenšek, F. & Russell, F.E. (1982). Neuromuscular and lethal effects of phospholipase A from *Vipera ammodytes* venom. *Toxicon*, Vol. 20, No. 6, pp. 1051–1058
- Tzeng, M.C., Yen, C.H., Hseu, M.J., Dupureur, C.M. & Tsai, M.D. (1995). Conversion of bovine pancreatic phospholipase A₂ at a single site into a competitor of neurotoxic phospholipases A₂ by site-directed mutagenesis. *Journal of Biological Chemistry*, Vol. 270, No. 5, pp. 2120–2123
- Valentin, E. & Lambeau, G. (2000). What can venom phospholipases A₂ tell us about the functional diversity of mammalian secreted phospholipases A₂? *Biochimie*, Vol. 82, No. 9–10, pp. 815–831
- Vardjan, N., Sherman, N.E., Pungerčar, J., Fox, J.W., Gubenšek, F. & Križaj, I. (2001). High-molecular-mass receptors for ammodytoxin in pig are tissue-specific isoforms of M-type phospholipase A₂ receptor. *Biochemical and Biophysical Research Communications*, Vol. 289, No. 1, pp. 143–149
- Vučemilo, N., Čopič, A., Gubenšek, F., & Križaj, I. (1998). Identification of a new high-affinity binding protein for neurotoxic phospholipases A₂. *Biochemical and Biophysical Research Communications*, Vol. 251, No. 1, pp. 209–212
- Ward, R.J., Chioato, L., De Oliveira, A.H.C., Ruller, R. & Sá, J.M. (2002). Active-site mutagenesis of a Lys49-phospholipase A₂: Biological and membrane-disrupting activities in the absence of catalysis. *Biochemical Journal*, Vol. 362, Pt. 1, pp. 89–96
- Yau, W.M., Wimley, W.C., Gawrisch, K. & White, S.H. (1998). The preference of tryptophan for membrane interfaces. *Biochemistry*, Vol. 37, No. 42, pp. 14713–14718
- Yu, B.Z., Berg, O.G. & Jain, M.K. (1993). The divalent cation is obligatory for the binding of ligands to the catalytic site of secreted phospholipase A₂. *Biochemistry*, Vol. 32, No. 25, pp. 6485–6492